Single-agent gemcitabine in patients with resistant small-cell lung cancer
I Van der Lee, EF Smit, JWG Van Putten, HJM Groen… - Annals of oncology, 2001 - Elsevier
Objective This study was conducted to assess the activity and toxicity of gemcitabine in
patients with resistant small-cell lung cancer (SCLC) Patients and methods Forty-one …
patients with resistant small-cell lung cancer (SCLC) Patients and methods Forty-one …
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597
GA Masters, L Declerck, C Blanke, A Sandler… - Journal of clinical …, 2003 - ascopubs.org
Purpose: Gemcitabine has shown a broad range of activity in solid tumors, including
previously untreated small-cell lung cancer (SCLC). The objective of this phase II trial was to …
previously untreated small-cell lung cancer (SCLC). The objective of this phase II trial was to …
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
T Hoang, KM Kim, A Jaslowski, P Koch, P Beatty… - Lung cancer, 2003 - Elsevier
Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite a dramatic initial
response, however, most patients relapse. Given the activity of gemcitabine in non-small cell …
response, however, most patients relapse. Given the activity of gemcitabine in non-small cell …
Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): a study of the National Cancer Institute of Canada Clinical Trials …
Y Cormier, E Eisenhauer, A Muldal, R Gregg, J Ayoub… - Annals of oncology, 1994 - Elsevier
Background The new pyrimidine antimetabolite Gemcitabine has shown preclinical efficacy
in a number of solid tumour lines and acceptable toxicity in phase I trials. As part of an …
in a number of solid tumour lines and acceptable toxicity in phase I trials. As part of an …
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
JP Sculier, JJ Lafitte, T Berghmans, J Thiriaux… - Lung Cancer, 2000 - Elsevier
The purpose of the present trial was to determine the activity of gemcitabine as a second-
line chemotherapy for non small cell lung cancer (NSCLC). To be eligible, patients had to …
line chemotherapy for non small cell lung cancer (NSCLC). To be eligible, patients had to …
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
F Ohyanagi, A Horiike, Y Okano, Y Satoh… - Cancer chemotherapy …, 2008 - Springer
Purpose To investigate the activity of gemcitabine combined with irinotecan in patients with
relapsed small cell lung cancer (SCLC). Patients and methods SCLC patients who had …
relapsed small cell lung cancer (SCLC). Patients and methods SCLC patients who had …
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study
C Dazzi, A Cariello, C Casanova, A Verlicchi… - Clinical lung cancer, 2013 - Elsevier
Background Although small-cell lung cancer is a chemosensitive malignancy, most patients
rapidly relapse. Results of second-line treatment are generally poor. We conducted a phase …
rapidly relapse. Results of second-line treatment are generally poor. We conducted a phase …
A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer
Purpose: To evaluate the efficacy and toxicity of the combination of gemcitabine and
docetaxel in pretreated patients with small-cell lung cancer (SCLC). Patients and methods …
docetaxel in pretreated patients with small-cell lung cancer (SCLC). Patients and methods …
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie …
JD Hainsworth, HA Burris III, JB Erland… - Cancer …, 2003 - Taylor & Francis
The purpose of the study was to evaluate the combination of gemcitabine and vinorelbine in
the treatment of patients with relapsed or refractory small cell lung cancer. Between March …
the treatment of patients with relapsed or refractory small cell lung cancer. Between March …
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
W Schuette, S Nagel, S Juergens, I Bork… - Clinical lung cancer, 2005 - Elsevier
BACKGROUND: Gemcitabine and irinotecan have shown a broad range of activity in solid
tumors, including smallcell lung cancer (SCLC), with a synergistic effect on SCLC cell lines …
tumors, including smallcell lung cancer (SCLC), with a synergistic effect on SCLC cell lines …